Glioblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones.
|
16598420 |
2006 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.
|
16697959 |
2006 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma.
|
16885506 |
2006 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma.
|
17175377 |
2007 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No significant association was observed between the EGF+61 polymorphism and glioblastoma or oligodendroglioma patients' overall survival.
|
17473192 |
2007 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To assess whether coselection of EGFR gains on 7p12 and monosomy 10 in glioblastomas promotes tumorigenic epidermal growth factor (EGF) signaling through loss of the annexin A7 (ANXA7) gene on 10q21.1-q21.2 and whether ANXA7 acts as a tumor suppressor gene by regulating EGFR in glioblastomas.
|
19602687 |
2009 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found 7 SNPs in haplotype 4 in EGF that were associated with prognosis in glioblastoma patients.
|
20197289 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A glioblastoma stem cell (GSC) line, GSC11, grows as neurospheres in serum-free media supplemented with EGF (epidermal growth factor) and bFGF (basic fibroblast growth factor), and, if implanted in nude mice brains, will recapitulate high-grade glial tumors.
|
20199106 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, EGF-induced glioblastoma migration requires both ERK1/2 and PI3K activity.
|
20392929 |
2010 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
EGF receptor variant III (EGFRvIII) is the most common variant of the EGF receptor and has been detected in a large percentage of patients with glioblastoma multiforme but not in normal brain.
|
20404701 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the genetic variants of EGFR, ERBB2, VEGFR and their ligands, EGF and VEGF on glioma and glioblastoma risk.
|
20446891 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
SNAI2 mRNA expression correlated with histologic grade and invasive phenotype in primary human glioma specimens, and was induced by EGF receptor activation in human glioblastoma cells.
|
20565806 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A bispecific ligand-directed toxin (BLT), called EGFATFKDEL, consisting of human epidermal growth factor, a fragment of urokinase, and truncated pseudomonas exotoxin (PE38) was assembled in order to target human glioblastoma.
|
20830604 |
2011 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, ectopic expression of α-catenin or depletion of β-catenin suppresses EGF-promoted glioblastoma cell migration, invasion, and proliferation.
|
20872274 |
2011 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma.
|
21503828 |
2011 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
|
21896743 |
2011 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of the Elk-1 led to an increased survival and a proliferative response with the EGF stimulation in the U138 glioblastoma cells.
|
22085529 |
2012 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In analyses of primary GBM tissue and RNA specimens, we found that GRK3 expression is correlated with established criteria for GBM subtyping including expression of EGF receptor, platelet-derived growth factor receptor (PDGFR)α, NF1, PTEN, CDKN2A, and neurofilament.
|
22086906 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The glioblastoma displayed EGF receptor amplification, and interestingly, it also displayed MYCN amplification; both tumors showed low level PTEN deletion.
|
22151431 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups suitable for such therapies.
|
22203985 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
High-level EGFR amplification was rapidly lost in 5 glioblastoma cultures supplemented with EGF, whereas it was preserved in cultures from the same tumors established without EGF.
|
22316604 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have observed levels of phosphorylation of STAT5 at position Y699 in cells expressing ΔEGFR that are similar or higher than in cells that overexpress EGFR and are acutely stimulated with EGF, prompting us to investigate the role of STAT5 activation in glioblastoma.
|
22729867 |
2013 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compensatory activation of related ERBB family receptors (ERBB2 and ERBB3) was observed in GBM CSCs deprived of EGFR signal (EGF deprivation or cetuximab inhibition), suggesting an intrinsic GBM resistance mechanism for EGFR-targeted therapy.
|
22745588 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
|
22891331 |
2012 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also observed that RhoG is activated by both HGF and EGF, two factors that are thought to be clinically relevant drivers of glioblastoma invasive behavior, and that RhoG is overexpressed in human glioblastoma tumors versus non-neoplastic brain.
|
22966858 |
2012 |